Linear oligopeptides. Part 406.¹ Helical screw sense of peptide molecules: the pentapeptide system $(Aib)_4/L$ -Val[L-(α Me)Val] in solution



Barbara Pengo,^{*a*} Fernando Formaggio,^{*a*} Marco Crisma,^{*a*} Claudio Toniolo,^{*a*} Gian Maria Bonora,^{*b*} Quirinus B. Broxterman,^{*c*} Johan Kamphuis,^{*d*} Michele Saviano,^{*e*} Rosa Iacovino,^{*e*,*f*} Filomena Rossi^{*e*} and Ettore Benedetti^{*e*}

^a Biopolymer Research Centre, CNR, Department of Organic Chemistry, University of Padova, 35131 Padova, Italy

^b Pharmaco-, Chemico-, Technological Department, University of Cagliari, 09124 Cagliari, Italy

^c DSM Research, Organic Chemistry and Biotechnology Section, PO Box 18, 6160 MD Geleen, The Netherlands

^d DSM Fine Chemicals, 6401 JH Heerlen, The Netherlands

^e Biocrystallography Research Centre, CNR, Department of Chemistry, University of Naples

"Federico II", 80134 Napoli, Italy

^f Faculty of Environmental Sciences, 2nd University of Naples, 81100 Caserta, Italy

A variety of N^{α} -blocked pentapeptide esters, each containing four helicogenic, achiral α -aminoisobutyric acid residues and one chiral L-valine or C^{α} -methyl-L-valine residue in the N-terminal, internal or C-terminal position of the sequence, have been synthesized by solution methods and fully characterized. The results of a solution conformational analysis, performed by using FTIR absorption and ¹H NMR techniques, favour the conclusion that all of the pentapeptides examined fold into a 3₁₀-helical structure. In addition, a CD study of the N^{α} -para-bromobenzoylated peptides strongly supports the view that the prevailing screw sense of the 3₁₀-helical structure that is formed is strongly dependent upon the position in the sequence of the single chiral C^{α} -tri- or C^{α} -tetrasubstituted α -amino acid.

Introduction

A project is currently underway in our laboratories aimed at understanding the factors governing the helical screw sense of peptide molecules. In particular, the exploitation of peptides based on the highly helicogenic α -aminoisobutyric acid (Aib), the prototype of C^{α} -tetrasubstituted α -amino acids, is extremely advantageous as in this case a rather stable helical structure may be easily formed in solvents of relatively low polarity at very short main chain lengths, *e.g.* with about five amino acid residues.^{2,3} This ordered peptide secondary structure is termed 3₁₀-helix,⁴ the helical parameters of which are very close to those of the classical α -helix. However, the intramolecular C=O···H=N hydrogen bonding schemes are significantly different in the two types of helical structure, being of the 1 \leftarrow 4 type or type-III (III') β -bend⁵ in the 3₁₀-helix, while of the 1 \leftarrow 5 type or α -bend⁶ in the α -helix.

Since Aib is an achiral residue, the helices adopted by its homo-oligomers do not exhibit a screw sense bias, the rightand left-handed forms being enantiomeric and hence isoenergetic and equally probable. However, if a chiral guest amino acid is incorporated in a host (Aib)_n sequence, the resulting 3₁₀helix is expected to exhibit a more or less markedly preferred screw sense, which will obviously be dependent on the absolute configuration and nature of the chiral residue. In the present work we have addressed the question of the effect induced in solution by an *additional* parameter, namely the *position* in the main chain of the chiral guest residue. As for the host sequence, we have designed an N^a-blocked, Aib-based, helical pentapeptide ester. As a guest residue, we have selected L-Val (a C^a-trisubstituted, protein a-amino acid) as well as its C^a- methylated counterpart, L-(α Me)Val (a strong helicogenic, C^{α} -tetrasubstituted α -amino acid).⁷ These two amino acids have been inserted either at the N-terminus (residue 1), or in an internal position (residue 3), or at the C-terminus (residue 5) of the pentapeptide main chain.

Experimental

FTIR absorption spectra

FTIR absorption spectra were recorded using a Perkin-Elmer model 1720X FTIR spectrophotometer (Norwalk, CT) nitrogen flushed, equipped with a sample-shuttle device, at 2 cm⁻¹ nominal resolution, averaging 100 scans. Solvent (baseline) spectra were recorded under the same conditions. Cells with path lengths of 0.1, 1.0 and 10 mm (with CaF₂ windows) were used. Spectrograde [²H]chloroform (99.8% ²H) was purchased from Merck (Darmstadt, Germany).

¹H NMR spectra

¹H NMR spectra were recorded with a Bruker model AM 400 spectrometer (Karlsruhe, Germany). Measurements were carried out in [²H]chloroform (99.96% ²H; Merck) and in [²H₆]DMSO ([²H₆]dimethyl sulfoxide) (99.96 ²H₆; Fluka, Buchs, Switzerland) with tetramethylsilane as the internal standard. The free radical TEMPO (2,2,6,6-tetramethylpiperidine-*N*-oxyl) was purchased from Sigma (Milwaukee, WI). The range of TEMPO concentration was $1.5-25 \times 10^{-3}$ mol dm⁻³.

CD spectra

CD spectra were recorded using a Jasco model J-600 spectro-

Table 1	Physical	properties and	l analytical	data for	the newly	synthesized	peptides	described	in this v	vork
---------	----------	----------------	--------------	----------	-----------	-------------	----------	-----------	-----------	------

		Mp/°C"	Recryst. solvent ^b		TLC ^a				
Compound	Yield (%)			$[a]_{\rm D}^{20c}$	$\overline{R_{\rm f}({\rm I})}$	R _f (II)	$R_{\rm f}({\rm III})$	<i>v</i> /cm ⁻¹ <i>e</i>	
Z-(Aib) ₄ -L-Val-OBu ^t	70	215–216	EtOAc	-42.5	0.75	0.95	0.25	3364, 3313, 1704, 1689, 1682, 1671, 1644, 1531	
Bz-(Aib) ₄ -L-Val-OBu ^t	77	233-234	EtOAc-LP	-38.1	0.70	0.95	0.20	3306, 1725, 1650, 1579, 1532	
pBrBz-(Aib) ₄ -L-Val-OBu ^t	86	228-229	MeCN	-38.1	0.80	0.95	0.25	3360, 3307, 1714, 1673, 1636, 1587, 1564, 1531	
pIBz-(Aib) ₄ -L-Val-OBu ^t	87	235-236	MeCN	-35.3	0.55	0.95	0.25	3437, 3315, 1713, 1671, 1587, 1530	
pNO ₂ Bz-(Aib) ₄ -L-Val-OBu ^t	90	225-226	MeCN	-37.1	0.50	0.95	0.20	3356, 3317, 1712, 1688, 1528	
pMeOBz-(Aib) ₄ -L-Val-OBu ^t	85	215–216	MeCN	-40.0	0.60	0.95	0.20	3437, 3370, 3329, 3302, 1714, 1666, 1636, 1574, 1533	
pDMABz-(Aib) ₄ -L-Val-OBu ^t	90	234–235	MeCN	-38.7	0.80	0.90	0.25	3362, 3330, 3301, 1711, 1667, 1650, 1622, 1525	
Z-(Aib)4-L-(aMe)Val-OBu'	85	214-215	EtOAc-LP	-21.3	0.80	0.95	0.25	3431, 3329, 1703, 1670, 1530	
$Bz-(Aib)_4$ -L-(αMe)Val-OBu ^t	88	245–246	CHCl ₃ -LP	-16.7	0.65	0.95	0.20	3423, 3298, 1732, 1722, 1658, 1644, 1579, 1534	
pBrBz-(Aib) ₄ -L-(αMe)Val-OBu ^t	78	227-228	MeCN	-16.9	0.75	0.95	0.20	3421, 3328, 1727, 1669, 1641, 1588, 1527	
p IBz-(Aib) ₄ -L-(α Me)Val-OBu ^t	89	224-225	EtOAc-LP	-36.9	0.50	0.95	0.25	3323, 1729, 1655, 1589, 1559, 1530	
$pNO_2Bz-(Aib)_4-L-(\alpha Me)Val-OBu^t$	86	250-251	MeCN	-23.2	0.45	0.95	0.20	3424, 3336, 1730, 1669, 1528	
p MeOBz-(Aib) ₄ -L-(α Me)Val-OBu ^t	84	222-223	EtOAc-LP	-38.2	0.60	0.95	0.20	3438, 3320, 1730, 1658, 1641, 1574, 1534	
pDMABz-(Aib) ₄ -L-(aMe)Val-OBu ^t	83	221-222	EtOAc-LP	-22.1	0.75	0.90	0.25	3434, 3376, 3351, 3330, 3302, 1710, 1688, 1625, 1522	
Z-L-Val-(Aib) ₄ -OBu ^t	74	181 - 182	EtOAc-LP	-25.1	0.65	0.95	0.25	3327, 1702, 1667, 1531	
<i>p</i> BrBz-L-Val-(Aib) ₄ -OBu ^{<i>t</i>}	88	235–236	EtOAc-LP	-32.7	0.65	0.95	0.30	3389, 3345, 1738, 1682, 1672, 1643, 1588, 1542, 1523	
pIBz-L-Val-(Aib) ₄ -OBu ^t	88	231-232	EtOAc-LP	-32.3	0.40	0.95	0.30	3345, 1735, 1645, 1586, 1538	
$Z-L-(\alpha Me)Val-(Aib)_4-OBu'$	55	194–195	EtOAc-LP	31.8	0.70	0.95	0.30	3433, 3330, 1733, 1666, 1640, 1532	
$pBrBz-L-(\alpha Me)Val-(Aib)_4-OBu'$	77	238–239	EtOAc-LP	28.6	0.60	0.95	0.25	3417, 3329, 1724, 1668, 1639, 1589, 1566, 1525	
Z-L-Val-(Aib)2-OBut	88	98–99	EtOAc-LP	-3.0	0.95	0.95	0.40	3325, 1729, 1703, 1657, 1529	
pBrBz-(Aib) ₂ -L-Val-(Aib) ₂ -OBu ^t	53	227-228	EtOAc-LP	31.4	0.50	0.95	0.20	3417, 3326, 1723, 1665, 1639, 1587, 1564, 1527	

^{*a*} Determined on a Leitz model Laborlux 12 apparatus (Wetzlar, Germany). ^{*b*} EtOAc, ethyl acetate, LP, light petroleum (bp 40–60 °C), MeCN, acetonitrile. ^{*c*} Determined on a Perkin-Elmer model 241 polarimeter (Norwalk, CT) equipped with a Haake model L thermostat (Karlsruhe, Germany); c = 0.5 (MeOH). ^{*d*} Silica gel plates (60F-254 Merck, Darmstadt, Germany) using the following solvent systems: (I) chloroform–ethanol 9:1; (II) butan-1-ol–acetic acid–water 6:2:2; (III) toluene–ethanol 7:1. The compounds were revealed either with the aid of a UV lamp or with the hypochlorite–starch–iodide chromatic reaction. A single spot was observed in each case. ^{*c*} Determined in KBr pellets on a Perkin-Elmer model 580 B spectrophotometer equipped with a Perkin-Elmer model 3600 IR data station and a model 660 printer.

polarimeter (Tokyo, Japan) equipped with a Haake thermostat (Karlsruhe, Germany). Cylindrical, fused quartz cells of 0.2 mm path lengths were employed. The data are expressed in terms of $[\theta]_{M}$, the total molar ellipticity (deg cm² dmol⁻¹). Methanol (C. Erba, Rodano, Milan, Italy) was used as solvent.

Results and discussion

Synthesis and characterization

For the large-scale production of the enantiomerically pure L- (αMe) Val we exploited an economically attractive and generally applicable chemo-enzymatic synthesis developed by the DSM group a few years ago.^{8,9} It involves a combination of organic synthesis for the preparation of the racemic α -amino acid amide followed by the use of a broadly specific amino acid amidase to achieve optical resolution.

The synthesis and characterization of eleven new L-Val and nine L-(α Me)Val pentapeptides were performed. Z-(Aib)₄-L-Val-OBu' and Z-(Aib)₄-L-(α Me)Val-OBu' were prepared using the oxazol-5(4*H*)-one from Z-(Aib)₄-OH.¹⁰ Z-L-Val-(Aib)₄-OBu' was synthesized from Z-L-Val-OH using the mixed anhydride method with isobutyl chloroformate, and Z-L-(α Me)Val-(Aib)₄-OBu' *via* the symmetrical anhydride method with [Z-L-(α Me)Val]₂O.⁷ Removal of the benzyloxycarbonyl N^{*a*}-protecting group was achieved by catalytic hydrogenation.

Incorporation of the benzoyl (Bz) group was obtained by treatment of the N^a -deprotected pentapeptide with benzoic anhydride. On the other hand, incorporation of the *para*-substituted Bz groups was achieved using the corresponding

1,2,3-benzotriazol-1-oxyl derivatives.¹¹⁻¹³ The synthesis of the pentapeptide with the L-Val residue in the central position was carried out from H-L-Val-(Aib)₂-OBu^{*t*} and the oxazol-5(4*H*)-one from *p*BrBz-(Aib)₂-OH.¹⁴ The synthesis and characterization of the N^{α} -para-bromobenzoylated pentapeptide with a central L-(α Me)Val residue have already been reported.⁷

The various peptides and their synthetic intermediates were characterized (Table 1) by melting point determination, optical rotatory power, TLC (in three solvent systems), solid-state IR absorption spectroscopy and ¹H NMR spectrometry (the latter data are not reported).

Solution conformational analysis

The conformational preferences adopted by the terminally blocked $(Aib)_4/L$ -Val and $(Aib)_4/L$ -(α Me)Val peptides were ascertained in the structure supporting solvents CDCl₃ (by FTIR absorption and ¹H NMR techniques) and MeOH (by CD spectroscopy). Fig. 1 illustrates the FTIR absorption spectra (N-H stretching region) and Figs. 2 and 3 the ¹H NMR data of six selected pentapeptides. The C=O····H-N intramolecular hydrogen-bonding pattern characterizing a 3₁₀-helical, N^{α} acylated pentapeptide sequence is reported in Fig. 4. Fig. 5 shows CD spectra of the same six N^{α} -para-bromobenzoylated pentapeptide sequences. The relevant parameters for the CD and UV absorption spectra of the N^{α} -benzoyl and N^{α} -parasubstituted benzoyl-peptides are listed in Table 2.

The FTIR absorption curves are characterized by bands at $3454-3431 \text{ cm}^{-1}$ (free, solvated NH groups) and at $3357-3347 \text{ cm}^{-1}$ (strongly hydrogen-bonded NH groups)¹⁵⁻¹⁷ (Fig. 1). No appreciable differences are seen in the spectra between 1×10^{-3}



Fig. 1 FTIR absorption spectra (3500–3250 cm⁻¹ region) of *p*BrBz-L-Xxx-(Aib)₄-OBu^{*t*} (A), *p*BrBz-(Aib)₂-L-Xxx-(Aib)₂-OBu^{*t*} (B), and *p*BrBz-(Aib)₄-L-Xxx-OBu^{*t*} (C) in CDCl₃ solution. Peptide concentration: 1×10^{-3} mol dm⁻³. Part (I): Xxx = L-Val; part (II): Xxx = L-(\alpha Me)Val.

and 1×10^{-4} mol dm⁻³ peptide concentration (results not shown). Therefore, the observed hydrogen bonding should be interpreted as arising almost exclusively from intramolecular C=O···H-N interactions. The intensity of the low-frequency band relative to the high-frequency band ($A_{\rm H}/A_{\rm F}$ ratio) is remarkable in all cases, suggesting the occurrence of a large population of intramolecularly hydrogen-bonded folded (helical) species. A comparison of the six curves shown in Fig. 1 indicates that the $A_{\rm H}/A_{\rm F}$ ratio is lower in the pentapeptides -L-Val-(Aib)₄- and -(Aib)₂-L-Val-(Aib)₂-, the only two sequences where L-Val residue is internal to the helical structure [in the pentapeptide -(Aib)₄-L-Val- the C-terminal L-Val residue is mostly external to the helical structure].

In summary, the FTIR absorption results are consistent with the hypothesis that in CDCl₃ solution all of the pentapeptides investigated are almost completely folded in an intramolecularly hydrogen-bonded helical conformation. Not surprisingly, the two C^{α} -tetrasubstituted residues Aib and (α Me)Val are found to be more efficient helix formers than the C^{α} -trisubstituted residue L-Val.^{3,7,18,19} To get more detailed information on the preferred conformations of these peptides in CDCl₃ solution we carried out a 400 MHz ¹H NMR investigation. The delineation of inaccessible (presumably intramolecularly hydrogen-bonded) NH groups by ¹H NMR was performed by using (i) solvent dependence of NH chemical shifts by adding increasing amounts of the hydrogen bonding acceptor DMSO^{20,21} to the CDCl₃ solution and (ii) free radical TEMPOinduced line broadening of NH resonances.²²

Unambiguous assignments have been performed only for the L-Val NH protons of the three (Aib)₄/L-Val pentapeptides *via* an inspection of their multiplicities and for the pentapeptide

 $-(Aib)_2-L-(\alpha Me)Val-(Aib)_2$ by means of a ROESY experiment,⁷ which allowed a sequential assignment of all its NH protons to be made.

In the six pentapeptides examined in the CDCl₃-DMSO mixtures and in the presence of the paramagnetic perturbing agent TEMPO two classes of NH protons were observed (Figs. 2 and 3). Class (i) includes protons whose chemical shifts are remarkably sensitive to the addition of DMSO and whose resonances broaden significantly upon addition of TEMPO. The fully (NH) assigned pentapeptide -(Aib)2-L-(aMe)Val-(Aib)₂- exhibits two protons of this type, N(1)H and N(2)H. All other five pentapeptides show an analogous behaviour (two protons of this type). In particular, also the N(1)H proton of -L-Val-(Aib)₄- is a member of this class. Class (ii) includes those protons displaying a behaviour characteristic of shielded protons (relative insensitivity of chemical shifts to solvent composition and of linewidths to the presence of TEMPO). The pentapeptide -(Aib)2-L-(aMe)Val-(Aib)2- exhibits three protons of this type, N(3)H to N(5)H. All other five pentapeptides behave similarly (three protons of this type). In particular, also the N(3)H and N(5)H protons of -(Aib)₂-L-Val-(Aib)₂- and -(Aib)₄-L-Val-, respectively, are members of this class.

In conclusion, these ¹H NMR results allow us to define the N(3)H to N(5)H protons of the pentapeptides as almost inaccessible to perturbing agents, and therefore, most probably, intramolecularly hydrogen bonded. This situation is indeed that expected for a pentapeptide in a regular 3_{10} -helix structure, characterized by three consecutive intramolecularly hydrogenbonded β -turns with the N(3)H to N(5)H protons acting as hydrogen bonding donors (Fig. 4). This conformational conclusion is supported by the observation of the L-Val ${}^{3}J_{\mathrm{HN}\alpha}$ coupling constants. In CDCl₃ solution (peptide concentration: 1×10^{-3} mol dm⁻³) and in the pentapeptides where the L-Val residue is either in the N-terminal or in an internal position of the sequence (*i.e.* inside the 3_{10} -helix), the ${}^{3}J_{\rm HN\alpha}$ value is in the range 5.9–6.2 Hz, implying a φ torsion angle²³ of about $-70^{\circ 24}$ (close to that expected for a 3₁₀-helical structure⁴). In contrast, in the pentapeptides where the L-Val residue is C-terminal (*i.e.* mostly external to the 3_{10} -helix) the ${}^{3}J_{HN\alpha}$ value is about 8.0 Hz, corresponding to consistently wider φ torsion angles, -90° or -145° , typical of more extended peptide conformations.

The screw sense of the 3₁₀-helical structure adopted by the pentapeptides was assessed by CD spectroscopy, by taking advantage of the para-bromobenzamido chromophore. In this connection we have recently reported that the para-bromobenzoyl group linked at the N-terminus of a peptide chain is an excellent CD probe for the assignment of the screw sense of 3_{10} -helical peptides, irrespective of the C^{α} configuration of the constituent a-amino acids.²⁵ Two oppositely signed bands are visible in the CD spectra of the six pentapeptides in MeOH solution illustrated in Fig. 4. The cross-over point between the two components of this exciton splitting is seen at 238 ± 1 nm, close to the region (241-242 nm) where the absorption maximum of the *para*-bromobenzamide chromophore is found.²⁶ A CD pattern with the positive component at higher wavelengths is indicative of the predominant population of a right-handed 310-helical structure.25 This same pattern is shown by the pentapeptides with the guest L-Val or L- (αMe) Val residue either at the N-terminus or in an internal position of the main chain. Conversely, the CD spectra of the -(Aib)₄-L-Val- and -(Aib)₄-L-(aMe)Val- pentapeptides (negative component at higher wavelengths) reflect a higher population of the left-handed 3_{10} helical structure. However, the lower dichroic intensities of the bands of these latter two pentapeptides compared to that of the former four pentapeptides might be, at least in part, interpreted as arising from a relatively modest predominance of the left-handed helix in the two compounds with the Cterminal, chiral guest residue [an additional factor responsible for this phenomenon might be that in the -(Aib)₄-L-Val- and



Fig. 2 Plots of NH chemical shifts in the ¹H NMR spectra of *p*BrBz-L-Xxx-(Aib)₄-OBu' (A), *p*BrBz-(Aib)₂-L-Xxx-(Aib)₂-OBu' (B), and *p*BrBz-(Aib)₄-L-Xxx-OBu' (C) as a function of increasing percentages of DMSO (v/v) added to the CDCl₃ solution. Peptide concentration: 1×10^{-3} mol dm⁻³. Part (I): Xxx = L-Val; part (II): Xxx = L-(α Me)Val. Unambiguously assigned NH proton resonances are explicitly indicated. For the assignment of the NH proton resonances of *p*BrBz-(Aib)₂-L-(α Me)Val-(Aib)₂-OBu' see ref. 7.

 $-(Aib)_4-L-(\alpha Me)Val$ - pentapeptides the distance between the N-terminal chromophore and the chiral centre is much longer].

Table 2 shows that the unsubstituted benzamido and all types of *para*-substituted benzamido chromophores examined give rise to an exciton splitting with signs of the Cotton effects paralleling those of the *para*-bromobenzamido chromophore discussed above. However, only in the Bz- and *p*BrBz-peptides, where the absorption maximum of the N-terminal chromophore (at 226 nm and 241–242 nm, respectively)²⁶ is closer to those of the peptide chromophore (below

230 nm),²⁷ the ellipticities of the CD bands are remarkably high and the exciton split is regular, *i.e.* the CD cross-over point is close to the UV absorption maximum and the dichroic intensities of the positive and negative maxima are comparable. In any event, these additional CD data confirm the screw sense of the -(Aib)₄-L-Val- and -(Aib)₄-L-(α Me)Valpentapeptides.

Taken together, our CD data favour the conclusion that the L-Val and L-(α Me)Val residues, when incorporated at the N-terminus or in an internal position of the peptide sequence preferentially induce a normal helix screw sense (*i.e.* an L-amino



Fig. 3 Plots of the bandwidths of the NH proton in the ¹H NMR spectra of *p*BrBz-L- Xxx-(Aib)₄-OBu' (A), *p*BrBz-(Aib)₂-L-Xxx-(Aib)₂-OBu' (B), and *p*BrBz-(Aib)₄-L-Xxx-OBu' (C) as a function of increasing percentages of TEMPO (w/v) added to the CDCl₃ solution. Peptide concentration: 1×10^{-3} mol dm⁻³. Part (I): Xxx = L-Val; part (II): Xxx = L-(α Me)Val. Unambiguously assigned NH proton resonances are explicitly indicated. For the assignment of the NH proton resonances of *p*BrBz-(Aib)₂-L-(α Me)Val-(Aib)₂-OBu' see ref. 7.



Fig. 4 The C=O···H–N intramolecular hydrogen-bonding pattern characterizing the 3_{10} -helical, N^{α} -acylated pentapeptide system studied in this work

acid gives a right-handed helical structure), while such a relationship is opposite when the chiral, guest residue is inserted at the C-terminus.

Conclusions

In this first systematic investigation^{28,29} of the preferred screw sense of the 3₁₀-helical peptides in solution we have designed a pentapeptide system based on four helicogenic, achiral Aib residues, the prototype of C^{α} -tetrasubstituted α -amino acids, and a single chiral α -amino acid, either C^{α} -trisubstituted (L-Val) or C^{α} -tetrasubstituted [L-(α Me)Val]. The conformational results obtained confirmed our working hypothesis, in the sense that in all of the compounds examined the 3₁₀-helical structure is indeed formed to a significant extent.

However, the most relevant information extracted from our chirospectroscopic data strongly supports the view that the pos-

Table 2 Relevant parameters for the CD and UV absorption spectra^{*a*} of the peptides discussed in this work

Peptide	$[\theta]_{\rm max}/10^3(\lambda)^b$	$\lambda_0^{\ c}$	$[\theta]_{\rm max}/10^3(\lambda)^a$	$\varepsilon/10^4 \left(\lambda_{\max}\right)^d$
Bz-(Aib) ₄ -L-Val-OBu ^t	-10.6 (239)	231	+16.8 (221)	1.3 (226)
Bz-(Aib) ₄ -L-(αMe)Val-OBu ^t	-8.2(239)	230	+8.6(222)	1.3 (226)
pBrBz-L-Val-(Aib) ₄ -OBu ^t	+22.5(247)	237	-26.6 (226)	1.7 (241)
pBrBz-(Aib) ₂ -L-Val-(Aib) ₂ -OBu ^t	+18.5(249)	239	-25.7 (229)	1.7 (242)
$pBrBz-(Aib)_4$ -L-Val-OBu ^t	-7.8(248)	238	+12.6(227)	1.6 (241)
$pBrBz-L-(\alpha Me)Val-(Aib)_4-OBu'$	+21.9(249)	238	-19.9 (229)	1.5 (241)
pBrBz-(Aib) ₂ -L-(aMe)Val-(Aib) ₂ -OBu ^t	+15.6(247)	237	-17.0(228)	1.7 (241)
$pBrBz-(Aib)_4-L-(\alpha Me)Val-OBu'$	-7.2 (249)	239	+9.9(229)	1.7 (241)
pIBz-L-Val-(Aib) ₄ -OBu'	+13.6(252)	240	-13.6 (216)	1.3 (253)
pIBz-(Aib) ₄ -L-Val-OBu'	-4.9 (258)	242	+7.0(222)	1.5 (253)
pIBz-(Aib) ₄ -L-(\alpha Me)Val-OBu'	-4.5 (257)	243	+4.2(232)	1.5 (253)
pMeOBz-(Aib) ₄ -L-Val-OBu ^t	-6.7 (255)	241	+11.0(227)	1.4 (254)
pMeOBz-(Aib) ₄ -L-(\alpha Me)Val-OBu'	-5.8 (255)	241	+8.4(230)	1.2 (255)
pNO_2Bz -(Aib) ₄ -L-Val-OBu ^t	-2.7(280)	260	+2.1(245)	0.9 (263)
$pNO_2Bz-(Aib)_4-L-(\alpha Me)Val-OBu^t$	-2.7(281)	260	+2.9(242)	1.0 (264)
pDMABz-(Aib) ₄ -L-Val-OBu ^t	-2.6(306)	264	+7.8(225)	2.0 (307)
pDMABz-(Aib) ₄ -L-(\alphaMe)Val-OBu ^t	-3.4 (300)	263	+6.1(227)	2.4 (307)

^{*a*} In methanol solution (peptide concentration: $1 \times 10^{-4} \text{ mol dm}^{-3}$). ^{*b*} $[\theta]_{\text{max}}$ is the total molar ellipticity (deg cm² dmol⁻¹) at λ_{max} (the wavelength in nm corresponding to the dichroic maximum). ^{*c*} Wavelength in nm corresponding to the cross-over point. ^{*d*} ε is the molar extinction coefficient at λ_{max} (the wavelength in nm corresponding to the UV absorption maximum).



Fig. 5 CD spectra in the 210–300 nm region of *p*BrBz-L-Xxx-(Aib)₄-OBu' (A), *p*BrBz-(Aib)₂-L-Xxx-(Aib)₂-OBu' (B), and *p*BrBz-(Aib)₄-L-Xxx-OBu' (C) in MeOH solution. Peptide concentration: 1×10^{-3} mol dm⁻³. Part (I): Xxx = L-Val; part (II): Xxx = L-(\alpha Me)Val.

ition where the single chiral residue is inserted in the main-chain is critical in directing 3_{10} -helical handedness. More specifically, if the chiral, helical residue is incorporated either at the Nterminal or in an internal position the relationship between α -carbon chirality and helical screw sense is that found in proteins (*i.e.* an L-amino acid gives a *right*-handed helix), whereas if the chiral residue is located at the C-terminus that relationship is 'inverse' (*i.e.* an L-amino acid gives a *left*-handed helix). Since this study has been conducted in solution, obviously crystal packing forces cannot be invoked ³⁰ as responsible for the experimentally observed data. Rather, we believe that the 'inverse' relationship described in this work might be explained on the basis of an unfavourable $O \cdots O$ interaction taking place between the carbonyl oxygen atom of the *i*-2 amino acid from the C-terminus and either oxygen atom of the ester functionality if the sign of the φ torsion angle of the C-terminal (*i*) residue is the same as that of the preceding 3₁₀-helical residues, and that this interaction can be removed by changing the sign of φ , *i.e.* by rotating it by 180° as illustrated in Fig. 6. Since in general L-amino acids have a strong tendency to adopt negative φ values,³¹ then it is not surprising that they would tend to induce a left-handed screw sense (positive φ values) in the



Fig. 6 (A) Model of a right-handed, 3₁₀-helical peptide *N*-alkyl amide, showing the C=O····H–N intramolecular hydrogen bond typical of the type-III β-turn conformation at the C-terminus (in this model the torsion angles φ_i , ψ_i are -60° , -60° , where *i* is the C-terminal residue). (B) Model of a right-handed 3₁₀-helical peptide *ester*, showing the unfavourable C-terminal interaction between the C=O oxygen of the *i*-2 residue and the C–OR oxygen of the *i* residue taking place if φ_i , ψ_i are -60° , -60° . (C) Model of a right-handed 3₁₀-helical peptide *ester*, showing the unfavourable C-terminal interaction between the C=O oxygen of the *i*-2 residue and the C=O oxygen of the *i* residue taking place if φ_i , ψ_i are -60° , $+120^\circ$. (D) Model of a right-handed 3₁₀-helical peptide *ester*, where φ_i , ψ_i are $+60^\circ$, -60° . (E) Model of a right-handed 3₁₀-helical peptide *ester*, where φ_i , ψ_i are $+60^\circ$, -120° . In models (D) and (E) the unfavourable O···O interaction is removed by rotation of the φ_i torsion angle by 180°.

preceding residues if located at the C-terminus of an otherwise achiral 3_{10} -helix.

Acknowledgements

The authors gratefully acknowledge M. U. R. S. T., the Ministry of University and of the Scientific and Technological Research, and the National Council of Research (C. N. R.) of Italy for their continuous and generous support to this research. The authors thank Dr Gabriella De Vita for technical assistance.

References

- 1 Part 405. C. Toniolo, M. Crisma and F. Formaggio, *Biopolymers* (*Pept. Sci.*), 1998, in press.
- C. Toniolo, G. M. Bonora, V. Barone, A. Bavoso, E. Benedetti,
 B. Di Blasio, P. Grimaldi, F. Lelj, V. Pavone and C. Pedone, *Macromolecules*, 1985, 18, 895.

- 3 C. Toniolo and E. Benedetti, *Macromolecules*, 1991, 24, 4004.
- 4 C. Toniolo and E. Benedetti, Trends Biochem. Sci., 1991, 16, 350.
- 5 C. M. Venkatachalam, Biopolymers, 1968, 6, 1425.
- 6 C. Toniolo, CRC Crit. Rev. Biochem., 1980, 9, 1.
- 7 C. Toniolo, M. Crisma, G. M. Bonora, B. Klajc, F. Lelj, P. Grimaldi, A. Rosa, S. Polinelli, W. H. J. Boesten, E. M. Mejer, H. E. Schoemaker and J. Kamphuis, *Int. J. Pept. Protein Res.*, 1991, 38, 242.
- 8 W. H. Kruizinga, J. Bolster, R. M. Kellogg, J. Kamphuis, W. H. J. Boesten, E. M. Mejer and H. E. Schoemaker, J. Org. Chem, 1988, 53, 1826.
- 9 H. E. Schoemaker, W. H. J. Boesten, B. Kaptein, H. F. M. Hermes, T. Sonke, Q. B. Broxterman, W. J. J. van den Tweel and J. Kamphuis, *Pure Appl. Chem.*, 1992, 64, 1171.
- 10 D. S. Jones, G. W. Kenner, J. Preston and R. C. Sheppard, J. Chem. Soc., 1965, 6227.
- 11 W. König and R. Geiger, Chem. Ber., 1970, 103, 788.
- 12 C. Toniolo, M. Crisma and F. Formaggio, *Biopolymers (Pept. Sci.)*, 1996, **40**, 627.
- 13 M. Crisma, G. Valle, V. Moretto, F. Formaggio, C. Toniolo and A. Albericio, *Letters Pept. Sci.*, 1998, in press.
- 14 C. Toniolo, G. M. Bonora, A. Bavoso, E. Benedetti, B. Di Blasio, V. Pavone and C. Pedone, *Macromolecules*, 1986, **19**, 472.
- 15 M. Palumbo, S. Da Rin, G. M. Bonora and C. Toniolo, *Makromol. Chem.*, 1976, **177**, 1477.
- 16 D. F. Kennedy, M. Crisma, C. Toniolo and D. Chapman, Biochemistry, 1991, 30, 6541.
- 17 C. Pulla Rao, R. Nagaraj, C. N. R. Rao and P. Balaram, Biochemistry, 1980, 19, 425.
- 18 F. Formaggio, M. Pantano, G. Valle, M. Crisma, G. M. Bonora, S. Mammi, E. Peggion, C. Toniolo, W. H. J. Boesten, H. E. Schoemaker and J. Kamphuis, *Macromolecules*, 1993, 26, 1848.
- 19 I. L. Karle and P. Balaram, *Biochemistry*, 1990, 29, 6747.
- 20 K. D. Kopple and M. Ohnishi, Biochemistry, 1969, 8, 4087.
- 21 D. Martin and G. Hauthal, in *Dimethyl Sulphoxide*, Van Nostrand-Reinhold, Wokingham, UK, 1975.
- 22 K. D. Kopple and T. J. Schamper, J. Am. Chem. Soc., 1972, 94, 3644. 23 IUPAC-IUB Commission on Biochemical Nomenclature, Bio-
- chemistry, 1970, 9, 3471. 24 K. Wütrich, in NMR of Proteins and Nucleic Acids, Wiley, New
- York, 1986, p. 167.
- 25 C. Toniolo, F. Formaggio, M. Crisma, H. E. Schoemaker and J. Kamphuis, *Tetrahedron: Asymmetry*, 1994, 5, 507.
- 26 N. Harada and K. Nakanishi, in *Circular Dichroic Spectroscopy: Exciton Coupling in Organic Stereochemistry*, University Science Books, Mill Valley, CA, 1983.
- 27 S. Beychok, in *Poly-a-Amino Acids*, ed. G. D. Fasman, Dekker, New York, 1967, p. 293.
- 28 E. Benedetti, A. Bavoso, B. Di Blasio, V. Pavone, C. Pedone, C. Toniolo and G. M. Bonora, *Proc. Natl. Acad. Sci. USA*, 1982, 79, 7951.
- 29 C. Toniolo, G. M. Bonora, A. Bavoso, E. Benedetti, B. Di Blasio, V. Pavone and C. Pedone, *Biopolymers*, 1983, 22, 205.
- 30 E. Benedetti, A. Bavoso, B. Di Blasio, V. Pavone, C. Pedone, M. Crisma, G. M. Bonora and C. Toniolo, J. Am. Chem. Soc., 1982, 104, 2437.
- 31 S. S. Zimmerman, M. S. Pottle, G. Némethy and H. A. Scheraga, *Macromolecules*, 1977, 10, 1.

Paper 8/006531 Received 23rd January 1998 Accepted 30th April 1998